Cancer Program Earns Reaccreditation From the Commission on Cancer

Jan 26, 2023

3 min

Nicholas J. Petrelli, M.D.

Report cited zero deficiencies and highlights leadership, innovative programs and strong research program


The Commission on Cancer, a quality program of the American College of Surgeons, has granted three-year reaccreditation to the cancer program at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, one of the original National Cancer Institute Community Cancer Centers Program sites in the U.S. ChristianaCare has received accreditation since 1951.


To earn accreditation, a cancer program must meet 34 quality care standards, be evaluated every three years through a survey process and maintain levels of excellence in the delivery of comprehensive patient-centered care.


The Commission cited zero deficiencies during its site visit and in its final report.



“Earning this prestigious accreditation with no deficiencies cited is a testament to the unparalleled expertise and quality of care our entire team at the Graham Cancer Center provides to our patients and community across the continuum of cancer care,” said Nicholas Petrelli, M.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute. “Patients in the communities we are privileged to serve can be assured of groundbreaking cancer treatments, innovative technology, state-of-the-art research, prevention, education and the most caring, dedicated team anywhere.”


“Innovative programs that address community need”


The Graham Cancer Center was recognized in the reaccreditation report for taking a multidisciplinary approach to treating cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists and other cancer specialists. This multidisciplinary partnership results in exceptional patient care.


In its performance report, the Commission on Cancer praised the Graham Cancer Center’s leadership that has built a “culture of continual process improvement across all areas from prevention, screening, treatment and support for the patient.”


It highlighted “innovative programs that address community need,” such as its on-site primary care practice and its Oncology Express Unit, which offers urgent care for patients with advanced disease.


The report also stated that the “research trial offerings are a strong point.” Clinical trials test new drugs and combinations of treatments, as well as new techniques using surgery, radiation therapy, gene therapy, immunotherapy and biologics. ChristianaCare is among the national leaders in cancer clinical trials; patient enrollment rates into clinical trials at the Graham Cancer Center are at 29% which is seven times the national average.


A national standard for accreditation


The Commission on Cancer accreditation program provides the framework for the Graham Cancer Center to improve its quality of patient care through various cancer-related programs that focus on the full spectrum of cancer care including prevention, early diagnosis, cancer staging, optimal treatment, rehabilitation, life-long follow-up for recurrent disease and end-of-life care.


When patients receive care at a Commission on Cancer-accredited facility, they also have access to information on clinical trials and new treatments, genetic counseling and patient-centered services including psycho-social support, a patient navigation process and a survivorship care plan that documents the care each patient receives and seeks to improve cancer survivors’ quality of life.


Like all Commission on Cancer-accredited facilities, the Graham Cancer Center maintains a cancer registry and contributes data to the National Cancer Database, a joint program of the Commission on Cancer and American Cancer Society. This nationwide oncology outcomes database is the largest clinical disease registry in the world. Data on all types of cancer is tracked and analyzed through the database and used to explore trends in cancer care. Cancer centers, in turn, have access to information derived from this type of data analysis, which is used to create national, regional and state benchmark reports. These reports help facilities with their quality improvement efforts.


Established in 1922 by the American College of Surgeons, the Commission on Cancer is a consortium of professional organizations dedicated to improving patient outcomes and quality of life for patients with cancer through standard-setting, prevention, research, education and the monitoring of comprehensive, quality care. There are currently more than 1,500 Commission on Cancer-accredited programs in the U.S. and Puerto Rico that diagnose and treat more than 70% of all patients newly diagnosed with cancer.


Connect with:
Nicholas J. Petrelli, M.D.

Nicholas J. Petrelli, M.D.

Bank of America Endowed Medical Director, Helen F. Graham Cancer Center and Research Institute

Nicholas J. Petrelli is a nationally recognized expert on cancer.

Colorectal CancerCancer Care ManagementCancer DetectionCancer clinical trialsSurgical Oncology
Powered by

You might also like...

Check out some other posts from ChristianaCare

4 min

Researchers Reveal How a Common Gene Mutation Disrupts Colon Tissue Renewal and Sparks Early Tumor Growth

A team of researchers from ChristianaCare and the University of Delaware has uncovered a key early step in how colorectal cancer begins. Their new study shows that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumors to form. Their findings were published in the journal Cancers. “This finding changes how we think about the very first steps of colon cancer,” said Bruce Boman, M.D., Ph.D., senior author of the study and a senior researcher at the Cawley Center for Translational Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. “Instead of cancer starting because cells grow too fast, we found that it may start because the normal tissue renewal process slows down, creating a backup of cells that should have moved on. That backup sets the stage for tumors to grow.” The study was led by a multidisciplinary team of engineers, mathematicians, pathologists and tumor biologists from four research institutions. Colorectal cancer is one of the most common and deadly cancers worldwide. According to the World Health Organization, more than 1.9 million people are diagnosed each year, and about 930,000 people die from the disease annually. How healthy colon tissue renews itself The lining of the colon is constantly renewing itself. Every day, billions of cells are shed and replaced to keep the tissue healthy and working properly. This process depends on a steady cycle. New cells form at the base of tiny pockets called crypts, mature as they move upward, and are eventually shed. The new study shows how this natural process breaks down when a mutation occurs in a gene called APC, which is altered in about 90 percent of colorectal cancers. Rather than speeding up cell growth, the APC mutation creates a slowdown, or bottleneck, in the colon tissue’s renewal cycle. According to Boman, this slowdown causes dividing cells to pile up instead of moving through the system as they should. The result is a kind of tumor cell “traffic jam” that leads to distorted tissue and the formation of adenomas, early growths that can become cancerous. What APC-mutant tissue looks like To see these changes up close, the team compared healthy colon tissue with tissue from patients who have familial adenomatous polyposis, or FAP, an inherited condition caused by APC mutations. The differences were clear: APC-mutant crypts contained more immature, rapidly dividing cells. Fewer cells matured into specialized cells needed for healthy tissue. The zone where cells divide extended higher than normal. The overall renewal cycle took longer. “These findings are significant because they show how cancer-driving mutations change tissues that normally renew themselves nonstop,” Boman said. Pairing patient tissue with computer modeling To see how these changes happen over time, the researchers studied patient tissue and used a computer model that shows how colon cells normally grow and renew. When they slowed this renewal process in the model, it matched what they saw in tissue with the APC mutation. Cells became crowded, the structures lost their normal shape, and early tumor-like growths, known as adenomas, began to form. This confirmed that delayed renewal alone can trigger the earliest changes linked to colon cancer, even before cells appear abnormal under a microscope. “Our findings show that APC mutation does more than turn on growth signals,” Boman said. “It changes the timing of renewal. Once that timing is off, the tissue becomes vulnerable to structural damage and early tumor growth.” Building on earlier research This study builds on earlier work by the same team that mapped how healthy colon tissue renews itself. In prior studies, the researchers identified five basic biological rules that guide how colon cells grow, move and replace one another in a steady, organized way. The new findings show what happens when that system breaks down. A common mutation called APC slows the normal renewal process. Young, stem-like cells begin to build up before they can mature. Over time, that imbalance creates the conditions for early tumor growth. To pinpoint how these changes unfold, researchers Gilberto Schleiniger, Ph.D., and Christopher Raymond, Ph.D., from the University of Delaware’s Department of Mathematical Sciences paired mathematical models with real patient tissue data. Their work shows that even small delays in cell renewal can push healthy tissue toward cancer. “This gives us a clearer picture of how cancer can start long before a tumor is visible,” said Schleiniger. “By understanding the rules that keep healthy tissue in balance, we can see where and how things begin to go off track.” A possible path toward future treatments The findings also point toward a potential new approach to treatment. The researchers found evidence that the disrupted renewal process may trigger a chain reaction that allows pre-cancerous cells to keep copying themselves and fueling tumor growth. By targeting this process, it may be possible to restore normal renewal timing and healthier tissue structure before cancer becomes established. “This study shows that cancer isn’t just about rogue cells, but about a system that’s fallen out of rhythm,” said Bruce Boman, M.D., Ph.D. “If we can reset that renewal process, we may be able to prevent or slow early tumor growth before it gains momentum.”

3 min

CorriXR Launches Bold Collaboration to Create First Inhaled CRISPR Therapy for Lung Cancer

CorriXR Therapeutics, ChristianaCare’s first commercial biotherapeutics spinout, has launched a major collaboration with InhaTarget Therapeutics and Merxin Ltd to develop an inhaled genetic therapy for lung cancer. The goal is to deliver a CRISPR-based treatment straight to tumors in the lungs to improve effectiveness and cut harmful side effects. A New Way to Treat Lung Cancer Lung cancer remains one of the deadliest cancers worldwide. Squamous cell lung carcinoma, an aggressive form of non-small cell lung cancer, accounts for up to 30% of cases. More than 380,000 people are diagnosed each year, yet the five-year survival rate stays under 15%. Standard chemotherapy and immunotherapy often become less effective, and many patients develop resistance that leaves them with few options and rising toxicity. CorriXR is taking aim at this problem. Its CRISPR gene editing system targets NRF2, a key driver of treatment resistance. By switching off NRF2, the therapy has the potential to make tumors sensitive to chemotherapy again and give patients a chance at better outcomes. As reported in a recent paper in Molecular Therapy Oncology, researchers at ChristianaCare’s Gene Editing Institute showed in preclinical lung cancer models that disabling NRF2 can resensitize tumors to chemotherapy with minimal off-target effects. “This partnership is about more than science. It’s about hope for patients,” said Eric Kmiec, Ph.D., founder and CEO of CorriXR Therapeutics and chief scientific officer at ChristianaCare’s Gene Editing Institute. “Lung cancer patients deserve therapies that work and improve quality of life. By combining our CRISPR-based technology with inhaled delivery, we can target tumors directly and reduce systemic toxicity. Our goal is to make treatment simpler, more effective and less invasive.” How the Inhaled Delivery System Works The treatment will be given through inhalation using InhaTarget’s lipid nanoparticle formulation delivered by Merxin Ltd’s advanced inhaler platform. The goal is a non-invasive therapy that patients could use at home. “Combining our pulmonary drug delivery LNP platform with CorriXR’s groundbreaking science and Merxin Ltd’s device technology has the potential to reshape the landscape of lung cancer treatment. We are eager to advance work on this novel combination,” said Frédéric De Coninck, Ph.D., co-founder and CEO of InhaTarget Therapeutics. Merxin Ltd’s technology is central to the approach. Its inhalers are built to deliver precise, consistent doses straight to the lungs. For this collaboration, Merxin Ltd is adapting its device to handle lipid nanoparticle formulations for the first time in a cancer treatment. “Our advanced inhaler technology is designed to ensure non-invasive, precise, consistent delivery of novel therapeutics,” said Philippe Rogueda, Ph.D., co-founder and chief business officer of Merxin Ltd. “We are excited to contribute to this vital effort and help bring innovative solutions to patients with lung cancer.” Why This Matters Patients with squamous cell lung carcinoma often face a fast-moving disease and few treatment choices. A therapy that can reach tumors directly, reduce toxicity and avoid resistance would mark a major shift. “This collaboration underscores the power of combining innovative science with practical delivery solutions,” said Kmiec. “Our CRISPR-based approach is designed to overcome one of the toughest challenges in oncology: treatment resistance. By partnering with experts in inhalation technology, we are moving closer to a therapy that is not only effective but accessible.” Studies will begin soon, with a substantial set of results on effectiveness and impact expected by spring 2026.

3 min

National Cancer Institute Renews Wistar—ChristianaCare Cancer Center Support Grant with Exceptional Score

The National Cancer Institute (NCI) has renewed the Cancer Center Support Grant (CCSG) for The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, awarding $16.3 million over the next five years. The renewal received an “exceptional” rating — the highest possible — recognizing the strength and impact of a partnership that combines world-class basic science with leading community-based cancer care. A One-of-a-Kind National Model This collaboration is the only one of its kind in the nation, joining Wistar, an NCI-Designated Basic Cancer Center, with ChristianaCare, one of the country’s premier academic community cancer centers and a National Cancer Institute Community Oncology Research Program. Together, they focus on driving advances against some of the most challenging cancers, including pancreatic, melanoma, breast, lung and ovarian cancers. The grant supports shared infrastructure, scientific resources and programs that enable researchers and clinicians to work seamlessly across both institutions. By connecting laboratory breakthroughs at Wistar with ChristianaCare’s ability to rapidly apply new approaches in a diverse patient population, the partnership accelerates the path from discovery to care. NCI highlighted the collaboration’s effectiveness, noting that “the ongoing alliance with the Helen F. Graham Cancer Center & Research Institute is where most clinical translation into active oncology trials is occurring, supported by productive collaboration between Wistar investigators and Graham Cancer Center oncologists.” Impact on Patients and Community “At ChristianaCare, we are committed to bringing innovation directly to the people we serve. Our collaboration with Wistar connects the best of basic science with the realities of patient care,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute. “The NCI’s exceptional score recognizes the promise of this work and the progress we are making together. It is a powerful affirmation that our patients are benefiting from research at the highest level.” “This renewal from the NCI is proof that we are building a model for how cancer research and community care can come together,” said Nicholas J. Petrelli, M.D., director of the Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute and associate director of Translational Research at The Wistar Institute Cancer Center. “Through our partnership with Wistar, patients in Delaware and beyond are gaining access to cutting-edge research and therapies for some of the toughest cancers we face.” Dario Altieri, M.D., president and CEO of The Wistar Institute and director of its Ellen and Ronald Caplan Cancer Center, added: “An exceptional rating from the NCI is a reflection of the scientific excellence and real-world impact of this partnership. What makes this collaboration unique is its ability to take discoveries in areas such as melanoma and ovarian cancer and bring them rapidly into clinical practice through ChristianaCare.” NCI underscored the alliance’s reach, noting that “the partnership with the Graham Cancer Center brought cutting-edge cancer research to the community and advanced groundbreaking discoveries to first-in-human oncology clinical trials.” A Pipeline of Research Advancing Faster Than Ever Research achievements supported by the Wistar—ChristianaCare partnership include: Advancing multiple Wistar discoveries into investigator-initiated, first-in-human oncology clinical trials, including studies in pancreatic, melanoma, lung, breast and ovarian cancers. Launching joint research programs across several cancer types, with expanding efforts in cancer risk and population health. Increasing access to high-quality biospecimens — including tumor tissue, biopsies and blood samples — that fuel translational research. Strengthening shared scientific infrastructure supporting immunotherapy research, organoid development, xenograft models and molecular profiling. The Wistar—ChristianaCare partnership, established in 2011, has grown into a nationally recognized alliance that bridges science and medicine. With this CCSG renewal, the collaboration will expand research in pancreatic, melanoma, breast, lung and ovarian cancers and continue advancing prevention, early detection and training programs for the next generation of physician—scientists. The Helen F. Graham Cancer Center & Research Institute depends on grants and community support to keep this work moving forward. To learn more or make a gift, visit Support the Helen F. Graham Cancer Center & Research Institute.

View all posts